Introduction
============

Dementia is a syndrome of acquired intellectual deficit resulting in significant impairment of social or occupational functions. Vascular cognitive dementia (VaD) comprises dementias resulting from all types of vascular pathologies. The current classification of VaD includes: cortical vascular dementia; subcortical ischemic dementia; strategic-infarct dementia; hypoperfusion dementia; hemorrhagic dementia; and dementias resulting from specific arteriopathies ([@b45-cia-0103-229]).

The diagnosis requires the presence of cognitive decline (loss of memory and deficits in at least two other domains) resulting in impaired functional abilities. Evidence of cerebrovascular disease (CVD) must be confirmed by neuroimaging for diagnosis of probable VaD and dementia and CVD must be reasonably related in time or temporally. Several specific diagnostic criteria can be used to diagnose VaD including the *Diagnostic Manual of Mental Disorders*, 4th edition (DMS-IV) criteria, the *International Classification of Diseases*, 10th edition criteria, the National Institute of Neurological Disorders and Stroke Association International pour le Recherché at L'Enseignement en Neurosciences (NINDS-AIREN) criteria, the Alzheimer's Disease Diagnostic and Treatment Centre criteria and the Hachinski Ischemic score.

The DSM-IV criteria have good sensitivity, but low specificity, but the NINDS-AIREN criteria are the most specific of all available criteria and are used most commonly in research (see Table [1](#t1-cia-0103-229){ref-type="table"}). As not all patients fulfill the strict criteria for dementia and many may be significantly cognitively impaired without memory loss, the term vascular cognitive impairment (VCI) has been suggested. VCI includes VaD, but also encompasses mixed Alzheimer's disease (AD) and VaD as well as vascular cognitive impairment without dementia and hereditary disorders. It is also becoming clear that there is an overlap between AD and CVD and the concept of mixed dementia has evolved. Patients will have clinical features of both AD and VaD and can share risk factors and pathogenic mechanisms ([@b38-cia-0103-229]). Diagnosis is complex due to the current lack of appropriate clinical criteria and terminology ([@b70-cia-0103-229]). However, in one recent Canadian cohort study (ACCORD), mixed dementia was found to represent as much as 33% of all dementias with "pure" VaD accounting for only 8.7% of dementia cases ([@b16-cia-0103-229]).

Prevalence
==========

VaD is historically considered the second most common cause of dementia in the elderly after AD ([@b28-cia-0103-229]). Between 1% and 4% of people over 65 years suffer from VaD ([@b22-cia-0103-229]) and the prevalence appears to double every 5--10 years after the age of 65 years ([@b24-cia-0103-229]). Post stroke dementia is extremely common and occurs in up to one third of patients with clinically evident ischemic stroke after 65 years ([@b63-cia-0103-229]; [@b49-cia-0103-229]). In a recent series ([@b9-cia-0103-229]) dementia was reported in 26.3% of patients at three months after stroke. The subtypes were 57.1% with VaD, 38.7% with AD and stroke, and 4.2% with other causes.

Pohjasvaara and colleagues (2002) reported cognitive decline of any kind to be present in 61.7% of stroke patients ranging in age from 55 to 85 years. The prevalence of mixed dementia is much harder to measure as the concept is relatively new and most studies have used pathological evidence, however it is clear that CVD and AD frequently co-exist in the elderly population ([@b62-cia-0103-229]; [@b23-cia-0103-229]; [@b44-cia-0103-229]). Autopsy series report that co-existing vascular pathology occurs in 24%--28% of AD cases ([@b18-cia-0103-229]) and conversely half of patients with vascular disease who have become demented also have AD pathology ([@b46-cia-0103-229]).

Clinical features
=================

Due to the variety of pathogenic mechanisms, the clinical manifestations of VaD can be varied and are determined by the size, location, and type of cerebral damage. Classically, the clinical features include an abrupt onset, stepwise deterioration, fluctuating course, and are often accompanied by focal motor and sensory abnormalities including early onset of urinary incontinence and gait disorders. However subcortical VaD can present with a gradual onset and deterioration like AD. Even within VaD, the clinical features can be further subdivided.

Cortical VaD
------------

This is characterized by abrupt onset of unilateral sensorimotor changes along with aphasia, apraxia, or agnosia (cortical cognitive impairments). In particular, most patients have an element of executive dysfunctioning leading to difficulties in areas such as initiation, planning, and organization of activities. There may be day to day fluctuations in severity with long plateaus between events ([@b14-cia-0103-229]).

Strategic infarct
-----------------

Single strategic infarcts will produce cognitive and other deficits that entirely depend on the location of the infarct. Particular areas known to produce acute onset VaD include the thalamus, basal forebrain, and caudate ([@b14-cia-0103-229]; [@b45-cia-0103-229]). Cognitively, memory impairment, impaired executive function, confusion, and fluctuating levels of consciousness may occur. Behavioral changes include apathy, lack of spontaneity and perseveration ([@b8-cia-0103-229]).

Subcortical VaD
---------------

Cerebrovascular lesions in the subcortical area tend to cause slow but episodic deterioration in executive functioning and abstract thought as well as mood changes including depression, personality changes, and emotional lability. Although memory deficits are less severe, the difficulties with complex tasks lead to decreased performance in activities of daily living (ADLs) ([@b55-cia-0103-229]).

With regard to the course of the disease as a whole, a recent study estimated median survival from dementia onset to death as 3.9 years for those with VaD as compared with 7.1 years for AD and 5.4 years for mixed dementia ([@b17-cia-0103-229]).

Risk factors for VaD
====================

Risk factors for VaD can be divided into two groups: modifiable and non-modifiable. The two most important non-modifiable risk factors are gender and age, followed by genetic predisposition, ethnicity, and a previous history of stroke. Both incidence and prevalence of VaD increase with age and tend to be higher in men ([@b71-cia-0103-229]; [@b24-cia-0103-229]; Ruitenburg et al 2001). Dementia affects around 7% of the general population older than 65 years and 30% of people older than 80. As previously mentioned the prevalence doubles every 5--10 years after the age of 65 years ([@b24-cia-0103-229]). Genetic defects for several monogenic disorders have been identified in the last decade. These include cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL) which is a cause of small vessel disease and stroke leading to cognitive impairment up to 20 years after the onset of symptoms. Other genetic disorders include hereditary cerebral hemorrhage with amyloidosis which leads to cognitive impairment or dementia in the majority of patients with this disorder ([@b64-cia-0103-229]).

Ethnicity appears to be of importance when one considers that previous studies suggest that VaD represents over 50% of dementias in Japan ([@b65-cia-0103-229]) (however there may have been differences in ascertainment of cases with over-diagnosis of VaD). Conversely, in a recent study of four major regional centers in China, the prevalence of dementia subtypes in China was comparable with that in Western countries ([@b72-cia-0103-229]).

There is a history of prior stroke in 76% of patients with vascular dementia and in 57% of those with vascular cognitive impairment as compared with only 5%--7% of people with AD ([@b52-cia-0103-229]).

The modifiable risk factors for VaD should be those that reduce CVD ie, hypertension, diabetes mellitus (DM), ischemic heart disease (IHD), peripheral vascular disease (PVD), white matter lesions, smoking, and hyperlipidemia ([@b10-cia-0103-229]; Meyer et al 1995; [@b52-cia-0103-229]).

Epidemiological data shows that hypertension is one of the most potent risk factors for VaD and it has been shown that control of hypertension can decrease the risk of VaD (In't [@b25-cia-0103-229]).

With regards to diabetes and the risk for VaD, [@b36-cia-0103-229] have shown that in a population of elderly subjects followed up for an average of 4.6 years, those with diabetes were over three times more likely to experience stroke-associated dementia.

White matter lesions seen on magnetic resonance imaging (MRI) scans of elderly patients with CVD strongly correlated with the development of dementia ([@b34-cia-0103-229]) implying that neuroimaging may prove a useful tool as a predictor of cognitive decline in post stroke patients.

Cognitive impairment is seen in 26% of patients discharged from hospital after treatment for heart failure, correlating with the degree of left ventricular dysfunction and systolic blood pressure levels below 130 mm Hg ([@b5-cia-0103-229]).

Coronary artery bypass graft (CABG) surgery is increasingly common, with a particular increase in the older population. In this group, widespread atherosclerotic disease can predispose to vascular sequele leading to neurological dysfunction. This has been the subject of a recent review ([@b57-cia-0103-229]). The reported incidence of early cognitive disturbance ranges from 33% to 83%. Long term cognitive outcome seems to be more favourable for off-pump CABG, but late post-operative dementia is predicted by early cognitive deterioration. It has also been suggested that aggressive post-operative risk factor control could favorably impact on cognitive outcome ([@b56-cia-0103-229]).

Dyslipidemia, a well established risk factor for ischemic heart disease, has not yet been convincingly demonstrated as a factor associated with VaD or AD. However, a recent cross sectional and prospective study of 4316 patients in the US showed that elevated levels of non-high-density lipoprotein cholesterol (non-HDL-C), low-density lipoprotein cholesterol (LDL-C) and decreased levels of HDL-C were weak risk factors for VaD ([@b51-cia-0103-229]).

The evidence for smoking and dementia is somewhat ambivalent however a recent study showed that current smokers had an increased risk of AD (relative risk \[RR\]=1.98; confidence index \[CI\]=1.63--5.42) and VaD (RR=1.98; CI=1.53--3.12) whereas past smokers did not have an increased risk of dementia ([@b29-cia-0103-229]) (Table [2](#t2-cia-0103-229){ref-type="table"}).

Prevention
==========

Primary prevention
------------------

Primary prevention aims to reduce the incidence of VaD by early detection and optimum treatment of known vascular factors for CVD and stroke ([@b45-cia-0103-229]). Targeting high risk groups (elderly patients, patients with hypertension, diabetes, atrial fibrillation, past transient ischemic attack or stroke, hypercholesterolemia, and smokers) affords the best chance of minimizing dementia in the population. As well as simple measures such as recommending lifestyle changes and optimizing control of diabetes, control of hypertension appears to be of paramount importance. Initially evidence for the effects of antihypertensive treatment on dementia was conflicting. Epidemiological data came from the Rotterdam study which was a longitudinal study of 7046 elderly and showed that the relative risk of vascular dementia was reduced by over one third over a mean of 2.2 years follow up in those who were receiving antihypertensives at baseline (In't [@b25-cia-0103-229]). Two subsequent prospective studies were less positive. The Medical Research Council (MRC) trial of hypertension in older adults with a diuretic/β blocker-based regimen showed no benefit in prevention of dementia ([@b43-cia-0103-229]) and the Systolic Hypertension in the Elderly Programme (SHEP) study showed no protective effect against dementia with treatment with diuretics +/−β blockers ([@b60-cia-0103-229]). However further evaluation of this trial has revealed that cognitive and functional evaluations may have been biased toward the null effect by differential dropout, thus obscuring the appraisal of a protective effect of treatment on the cognitive and functional decline ([@b11-cia-0103-229]). More positive evidence came in the form of the Systolic Hypertension in Europe trial which demonstrated a 55% reduction in the incidence of dementia in the active treatment group (receiving a calcium channel blocker) over two years. However only small numbers of new cases of dementia were identified and therefore the results should be interpreted with caution ([@b47-cia-0103-229]).

Secondary prevention
--------------------

In secondary prevention, the target is stroke management and prevention of recurrent stroke. More recently, the Perindopril Protection Against Recurrent Stroke Study (PROGRESS) trial confirmed the benefits of blood pressure lowering in secondary prevention ([@b50-cia-0103-229]). Although the primary outcome of PROGRESS was stroke incidence, dementia and cognitive function were secondary outcomes. The active treatment group received the long-acting angiotensin-converting enzyme (ACE) inhibitor perindopril combined with the diuretic indapamide. After four years of follow up in the entire population, the reduction in risk of dementia in the active treatment group was 12% (not significant). However, a significant reduction in dementia of 34% in the active treatment group was observed in patients with recurrent stroke (p=0.03). A similar pattern was seen for cognitive decline with an overall risk reduction of 19% with active treatment in the whole population (p=0.01) but a significant risk reduction of 45% in the group with prior stroke (p=0.001). Combination therapy induced a mean difference of blood pressure of 12/5 mm Hg and was more effective in reducing the risk of dementia than monotherapy, the difference of blood pressure on monotherapy being 5/3 mm Hg.

Among the patients without cognitive impairment at baseline, a 50% reduction in the risk of dementia was seen in those with prior stroke compared with a 16% reduction in those without stroke.

Further evidence was demonstrated in a PROGRESS sub study (MRI study). This looked at whether blood pressure lowering could arrest the progression of white matter hyperintensities (WMH). We know that WMH are associated with cognitive impairment or dementia ([@b3-cia-0103-229]; [@b35-cia-0103-229]; [@b67-cia-0103-229]) and are often observed on brain MRI in elderly patients ([@b2-cia-0103-229]; [@b3-cia-0103-229]; [@b33-cia-0103-229]; [@b35-cia-0103-229]; [@b13-cia-0103-229]) and those who have suffered a stroke ([@b40-cia-0103-229]; [@b66-cia-0103-229]; [@b26-cia-0103-229]). At 36 months the mean total volume of new WMHs was significantly reduced in the active treatment group receiving perindopril +/− indapamide (p=0.012), therefore the results indicated that an active blood-pressure lowering regimen stopped or delayed the progression of WMHs in patients with CVD ([@b12-cia-0103-229]).

The treatment of another risk factor, hypercholesterolemia, has also become topical. It is clear that the use of 3-hydroxy-3 methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (ie, statins) have a well defined role in the secondary prevention of stroke. What is less obvious is their role in preventing cognitive decline. Observational studies have suggested that treatment with statins lower the risk of developing dementia or cognitive decline however most of the available data does not distinguish between AD, VaD and other forms of dementia ([@b27-cia-0103-229]; [@b32-cia-0103-229]; [@b53-cia-0103-229]). The Heart Protection Study which investigated the effects of simvastatin on vascular outcomes including stroke, showed no significant benefit of simvastatin on 5-year cognitive outcomes ([@b21-cia-0103-229]). However, the study design for this particular outcome could be criticized as there was no measure of baseline cognitive function. The Prospective Study of Pravastatin in the Elderly at Risk study (PROSPER) followed 6000 individuals aged 70 to 82 for 3.2 years. Pravastatin reduced the risk of coronary disease in elderly individuals but had no significant benefit on stroke, cognition, or ADL. It has been hypothesized though, that the studies involving statins have been of insufficient duration to detect cognitive benefits ([@b61-cia-0103-229]).

Other less studied strategies for prevention of VaD focus on prompt stroke diagnosis and treatment and good after care. They should impact on cognitive function at least through event reduction. These include: early intervention (within 3 hours) in selected patients with stroke to achieve reperfusion with thrombolytic agents, antiplatelet agents for patients with past transient ischemic attack (TIA) or non-hemorrhagic stroke, anticoagulants for atrial fibrillation as indicated, carotid endarterectomy for severe carotid stenosis and intensive rehabilitation after stroke ([@b59-cia-0103-229]).

Symptomatic treatment
=====================

Initial studies of several agents in VaD including vasodilators, nootropics, antithrombotics, ergot alkaloids, antioxidants, hyperbaric oxygen and thyrotropin-releasing hormone analogue have had mostly negative results ([@b14-cia-0103-229]; [@b54-cia-0103-229]). However the study designs were not ideal as they were based on small numbers, had short treatment periods and there were varying end points of the various trials.

Propentofylline is a glial modulator which has been studied in more detail. Several double blind, placebo-controlled randomized, parallel group trials carried out in Europe and Canada showed significant symptom improvement and long term efficacy in the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog) and Clinician's Interview Based Impression of Change (CIBIC-plus) up to 48 weeks compared with placebo ([@b31-cia-0103-229]; [@b39-cia-0103-229]). The calcium antagonist nimodipine which is known to have specific effects on small vessels was studied in a double-blind, placebo controlled study in VaD. Although there was no overall evidence of efficacy in VaD, nimodipine had beneficial effects on attention and psychomotor performances in the subcortical group ([@b48-cia-0103-229]).However, the effects appear to be short term. Memantine, which is a moderate affinity noncompetitive N-methyl-D-aspartate receptor antagonist, is another treatment which shows promise and is well tolerated. It is licensed for use in moderate AD but a number of studies of memantine in VaD have shown improvement in mini-mental state examination (MMSE) as well as functional levels and reduced care dependency compared with placebo. Interestingly, the cognitive treatment effect for memantine was more pronounced in the small vessel group ([@b19-cia-0103-229]; [@b41-cia-0103-229]; [@b68-cia-0103-229]).

There is growing evidence for cholinergic involvement in VaD. Autopsy patients with VaD have shown significantly reduced choline acetyl-transferase activity in several brain regions including the caudate and putamen, hippocampus and temporal lobe cortex ([@b20-cia-0103-229]). This equates to a 40% loss of cholinergic neurons as compared with 70% in AD cases ([@b6-cia-0103-229]). Again, in rodent models such as the stroke-prone spontaneously-hypertensive rats, there is a significantly reduced level of cholinergic markers including acetylcholine in the neocortex, hippocampus, and cerebrospinal fluid that appears to correlate with impaired learning and memory ([@b20-cia-0103-229]; [@b30-cia-0103-229]). It is reasonable therefore to hypothesize that in a similar way to AD, enhancing cholinergic transmission may be a rational approach to treatment of VaD. As a result, three of the acetylcholinesterase inhibitors approved for use in AD: donepezil, rivastigmine, and galantamine have also been used in VaD. Rivastigmine is a second generation cholinesterase inhibitor with the capacity to inhibit both acetylcholinesterase and butyrylcholinesterase. In a randomized open label one year study, 208 patients with VaD were treated with rivastigmine. There was slight improvement in executive function (clock drawing tests) and in behavior ([@b42-cia-0103-229]), however the results of a randomized double-blind trial with rivastigmine are awaited. The most positive results have been seen with donepezil and galantamine. Donepezil is a piperidine-based agent and is a noncompetitive, reversible antagonist of cholinesterase and is highly selective for acetyl-cholinesterase. Efficacy and safety has been shown in two large randomized placebo-controlled trials ([@b1-cia-0103-229]; [@b69-cia-0103-229]) and confirmed in a recent Cochrane review ([@b37-cia-0103-229]). Altogether 1219 patients with VaD, according to the NINDS-AIREN criteria, were recruited for 24 week trials. The patients were randomized to one of three groups: placebo, donepezil 5 mg per day, or donepezil 10 mg per day. From week 6 through week 24 both active treatment groups showed statistically significant improvement in cognitive, global function, and ADLs as compared with placebo and the drug was well tolerated. Galantamine is a cholinesterase inhibitor that also modulates central nicotinic receptors. In a multicenter, double-blind 6 month randomized control trial, patients diagnosed with probable VaD or AD combined with CVD received galantamine or placebo. Primary end points were cognition and global functioning and secondary end points included assessment of behavioral symptoms according to the Neuropsychiatric Inventory (NPI) and ADL using the Disability Assessment in Dementia (DAD) ([@b7-cia-0103-229]). In analysis of both groups as a whole, galantamine demonstrated efficacy on all outcome measures. It showed greater efficacy than placebo on ADAS-cog (2.7 points; p\<0.001) and CIBIC-plus (74% vs 59% of patients remained stable or improved; p\<0.001). ADL and behavioral symptoms were also significantly improved compared with placebo (both p\<0.05) ([@b15-cia-0103-229]). Although the overall population showed improvement, the VaD subgroup changes did not achieve significance. There are two further large randomized controlled trials in VaD with galantamine awaiting publication. Preliminary results have shown that while benefits were seen for galantamine in executive dysfunction and cognition, the global outcomes were unaffected.

Conclusion
==========

Vascular dementia is a common condition and its prevalence is likely to increase. As physicians we need to be diligent with regards to recognition of risk factors and vigorous intervention. Promising results have been seen in several clinical trials of cholinesterase inhibitors and no safety or tolerability issues have been noted.

###### 

NINDS-AIREN criteria for diagnosis of vascular dementia

  **Dementia**
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cerebrovascular disease: Focal CNS signsEvidence of CVD by brain imagingA relationship between the two manifested by one or more of the following: Dementia onset within three months after having a strokeAbrupt deterioration in cognition or fluctuating stepwise course

**Abbreviations:** CNS, central nervous system; CVD, cardiovascular disease; NINDS-AIREN, National Institute of Neurological Disorders and Stroke Association International pour le Recherché at L'Enseignement en Neurosciences.

###### 

Common risk factors for vascular dementia

  ---------------------
  Age
  Gender (male)
  Ethnicity
  Hypertension
  Atherosclerosis
  Hyperlipidemia
  Diabetes mellitus
  Smoking
  Atrial fibrillation
  Hyperhomocystinemia
  ---------------------
